Cidara Therapeutics

Cidara is a clinical-stage biotechnology company dedicated to developing new anti-infective drugs that have the potential to change the standard of care and save or improve patients' lives. The company’s portfolio includes novel approaches aimed at transforming existing treatment and prevention paradigms, starting with its lead Phase 3 antifungal candidate, rezafungin, and drug-Fc conjugates (DFCs) targeting viral and oncologic diseases from Cidara's proprietary Cloudbreak® platform.